Genomma Lab Internacional. de Balans Gezondheid
Financiële gezondheid criteriumcontroles 5/6
Genomma Lab Internacional. de heeft een totaal eigen vermogen van MX$11.2B en een totale schuld van MX$6.6B, wat de schuld-eigenvermogensverhouding op 59.1% brengt. De totale activa en totale passiva bedragen respectievelijk MX$23.5B en MX$12.4B. De EBIT Genomma Lab Internacional. de is MX$3.7B waardoor de rentedekking 4.2 is. Het heeft contanten en kortetermijnbeleggingen van MX$1.8B.
Belangrijke informatie
59.1%
Verhouding schuld/eigen vermogen
Mex$6.59b
Schuld
Rente dekkingsratio | 4.2x |
Contant | Mex$1.83b |
Aandelen | Mex$11.15b |
Totaal verplichtingen | Mex$12.36b |
Totaal activa | Mex$23.51b |
Recente financiële gezondheidsupdates
Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
Oct 17These 4 Measures Indicate That Genomma Lab Internacional. de (BMV:LABB) Is Using Debt Reasonably Well
May 31Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly
Jan 29Is Genomma Lab Internacional. de (BMV:LABB) Using Too Much Debt?
Mar 31Does Genomma Lab Internacional. de (BMV:LABB) Have A Healthy Balance Sheet?
Dec 07Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
Jul 27Recent updates
Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
Oct 17Calculating The Intrinsic Value Of Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)
Sep 11With Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) It Looks Like You'll Get What You Pay For
Jul 12These 4 Measures Indicate That Genomma Lab Internacional. de (BMV:LABB) Is Using Debt Reasonably Well
May 31Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly
Jan 29Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 49% Discount?
Nov 07Is Genomma Lab Internacional. de (BMV:LABB) Using Too Much Debt?
Mar 31Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 32% Discount?
Feb 24Does Genomma Lab Internacional. de (BMV:LABB) Have A Healthy Balance Sheet?
Dec 07Rainbows and Unicorns: Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Analysts Just Became A Lot More Optimistic
Sep 24Analysts Just Made A Major Revision To Their Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Revenue Forecasts
Aug 01Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
Jul 27Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly
Mar 22Are Investors Undervaluing Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) By 44%?
Feb 15Genomma Lab Internacional. de (BMV:LABB) Seems To Use Debt Quite Sensibly
Nov 24Here's Why I Think Genomma Lab Internacional. de (BMV:LABB) Is An Interesting Stock
Sep 08Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Intrinsic Value Is Potentially 96% Above Its Share Price
Jun 10Is Genomma Lab Internacional. de (BMV:LABB) A Risky Investment?
May 24Should You Be Adding Genomma Lab Internacional. de (BMV:LABB) To Your Watchlist Today?
May 06Investors Who Bought Genomma Lab Internacional. de (BMV:LABB) Shares Five Years Ago Are Now Up 65%
Mar 13Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
Feb 19Do Its Financials Have Any Role To Play In Driving Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Stock Up Recently?
Feb 02Are Investors Undervaluing Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) By 42%?
Jan 15What Is The Ownership Structure Like For Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)?
Dec 28Genomma Lab Internacional. de (BMV:LABB) Shareholders Have Enjoyed A 54% Share Price Gain
Dec 10Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( MX$12.2B ) LAB B } overtreffen de korte termijn passiva ( MX$6.7B ).
Langlopende schulden: De kortetermijnactiva LAB B ( MX$12.2B ) overtreffen de langetermijnschulden ( MX$5.6B ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 42.7% ) LAB B wordt als hoog beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van LAB B is de afgelopen 5 jaar gedaald van 74.3% naar 59.1%.
Schuldendekking: De schuld van LAB B wordt goed gedekt door de operationele kasstroom ( 39% ).
Rentedekking: De rentebetalingen op de schuld van LAB B worden goed gedekt door EBIT ( 4.2 x dekking).